Patrick Griffith, MD
Interventional Pain Medicine · North Kansas City, MONPI 1366524076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 44.2% of the total. Reporting peaked in 2023 at $1,067 and has fallen 97.9% since, to $23 in 2025.
Across 247 payments — averaging $13.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Boston Scientific$571
- Nevro Corp.$540
- Relievant Medsystems, Inc.$293
- SPR Therapeutics, Inc$212
- Abiomed$168
- plus $24 from 2 others
What the payments were for
- Travel & lodging$2648%
- Food & beverage$2,97092%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 219 | $1,432 |
| Boston Scientific | 9 | $571 |
| Nevro Corp. | 10 | $540 |
| Relievant Medsystems, Inc. | 3 | $293 |
| SPR Therapeutics, Inc | 3 | $212 |
| Abiomed | 1 | $168 |
| Vertos Medical, Inc. | 1 | $14 |
| Saluda Medical Americas, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$1,277
- INTELLIS ADAPTIVESTIM$344
- INTELLIS$270
- Omnia$261
- Impella$168
- VECTRIS$140
- SPRINT PNS System$118
- Senza$105
How this compares
$3,239 in reported general payments places this provider in the 55th percentile of 27 interventional pain medicine providers in Missouri.
See all interventional pain medicine providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 506 | $11,079 |
| Pregabalin | 238 | $5,815 |
| Gabapentin | 279 | $5,409 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 169 | $5,082 |
| Oxycodone Hcl | 176 | $3,932 |
| Morphine Sulfate ErMorphine Sulfate | 71 | $1,572 |
| Tramadol Hcl | 159 | $1,379 |
| Baclofen | 45 | $920 |
| Duloxetine Hcl | 39 | $862 |
| Methadone Hcl | 29 | $589 |
| Celecoxib | 14 | $560 |
| Tizanidine Hcl | 40 | $361 |
| Hydromorphone Hcl | 14 | $275 |
| Ibuprofen | 11 | $222 |
| Lorazepam | 92 | $194 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in North Kansas City
- Sean ClinefelterNorth Kansas City$2K
- Danish ZaidiNorth Kansas City$2K
- Rebecca SandersJoplin$209K
- Ramis GheithBridgeton$73K
- Helen BlakeChesterfield$48K
- Andrew FrazierKansas City$32K
- Christian OliverBridgeton$18K
- David TonkinSpringfield$14K
- Dwayne JonesKansas City$11K
- Bradford NobleColumbia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.